Category: Parkinson’s News

Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

The advisory board member of the Parkinson’s Foundation shared personal insights on how love, present-moment awareness, and hope shaped her approach to living with the Parkinson disease. [WATCH TIME: 6 minutes]

Canberra’s Parkinson’s community has long been campaigning for the ACT government to employ a specialist Parkinson’s nurse who can visit patients at home. The ACT government says planning is underway to create the position but a start date has yet to be confirmed.

A new study reveals that long-term adaptive cycling can measurably reshape brain signals in people with Parkinson’s Disease, offering clues into how exercise relieves motor symptoms.

Parkinson’s disease affects nearly a million Americans — and as our population ages, that number is growing. But there’s hope. New research and cutting‑edge treatments, from deep brain stimulation to breakthrough medications, are changing lives.

Luke Evison, whose brother was diagnosed with Parkinson’s Disease aged 45, sets off on Sunday.

Insightec, the Miami-based innovator in focused ultrasound to transform patient care, announced July 8 the U.S. Food and Drug Administration approved the use of its Exablate Neuro platform for staged bilateral pallidothalamic tractotomy treatment in patients living with advanced Parkinson’s disease.

Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23. Global net revenues from the immunology portfolio were $7.63 billion, up 9.5% (+9.2% on an operational basis), including-Skyrizi sales increased 62.2% (+61.8%) to $4.42 billion; Rinvoq s